AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s TROP2-targeted antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) should have a role in the treatment of some lung and breast cancers on the basis of data from their TROPION-Lung01 and TROPION-Breast01 Phase III studies, presented at the European Society for Medical Oncology congress in Madrid, Spain.
ESMO 2023: TROPION-Breast01 And -Lung01 Studies Breathe Life Into Dato-DXd
The future for AstraZeneca/Daiichi Sankyo’s TROP2-targeted ADC candidate Dato-DXd is looking more positive after details of their TROPION-Lung01 and TROPION-Breast01 Phase III studies were presented at ESMO.
